Physician profile
Christopher P Karcher
NPI 1194810408
$25,906.49
in general payments reported to CMS, 2019-2025
62 companies · $3,927 in 2025
The $3,927 reported for 2025 was more than what 86% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,042 · 2020: $2,592 · 2021: $3,562 · 2022: $3,690 · 2023: $4,554 · 2024: $4,540 · 2025: $3,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $28.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,993.01 |
| Education | $28.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,604.97 | 2021-2025 | |
| Ucb, INC. | $2,114.40 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Acadia Pharmaceuticals INC | $1,892.64 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $1,665.69 | 2019-2025 | |
| Sk Life Science, INC. | $1,277.17 | 2020-2025 | |
| Amgen INC. | $1,248.12 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $1,187.30 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $1,173.15 | 2021-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $1,169.49 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Pfizer INC. | $889.78 | 2019-2025 | |
| Lundbeck LLC | $778.99 | 2020-2025 | Vyepti, Rexulti |
| Biogen, INC. | $724.74 | 2019-2025 | Vumerity, Tysabri |
| Allergan, INC. | $690.21 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $584.61 | 2019-2022 | |
| Horizon Therapeutics Plc | $552.65 | 2021-2023 | Uplizna |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Karcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.